研究業績（原著と症例報告のみ） 2022年

原著論文
1.
Development of Hepatocellular Carcinoma in Patients Aged 75-84 Years With Chronic Hepatitis C Treated With Direct-Acting Antivirals Ogawa E, Nomura H, Nakamuta M, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Ooho A, Azuma K, Takahashi K, Satoh T, Koyanagi T, Ichiki Y, Kuniyoshi M, Yanagita K, Amagase H, Morita C, Sugimoto R, Kato M, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group.
J Infect Dis. 2022 Aug 26;226(3):431-440.
2.
Long-term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct-acting antivirals.
Ogawa E, Nakamuta M, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Ooho A, Azuma K, Takahashi K, Satoh T, Koyanagi T, Yamashita N, Ichiki Y, Yamashita N, Kuniyoshi M, Yanagita K, Amagase H, Morita C, Sugimoto R, Kato M, Shimoda S, Nomura H, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group.
J Gastroenterol Hepatol. 2022 Jan;37(1):190-199.
3.
Long-term hepatic function of patients with compensated cirrhosis following successful direct-acting antiviral treatment for hepatitis C virus infection.
Ogawa E, Kawano A, Ooho A, Furusyo N, Satoh T, Takahashi K, Kajiwara E, Dohmen K, Nakamuta M, Azuma K, Koyanagi T, Yamashita N, Yanagita K, Ichiki Y, Kuniyoshi M, Yamashita N, Morita C, Sugimoto R, Kato M, Shimoda S, Nomura H, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group.
J Gastroenterol Hepatol. 2022 Feb;37(2):371-377.
4.
Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study.
Ogawa E, Nakamuta M, Koyanagi T, Ooho A, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Satoh T, Takahashi K, Azuma K, Yamashita N, Yamashita N, Sugimoto R, Amagase H, Kuniyoshi M, Ichiki Y, Morita C, Kato M, Shimoda S, Nomura H, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Hepatol Int. 2022 Apr;16(2):282-293.
5.
Dynamics of anti-Spike IgG antibody level after the second BNT162b2 COVID-19 vaccination in health care workers. Ikezaki H, Nomura H, Shimono N.
J Infect Chemother. 2022 Jun;28(6):802-805.
6.
A case of severe COVID-19 with pulmonary thromboembolism related to heparin-induced thrombocytopenia during prophylactic anticoagulation therapy.
Sasaki K, Murata M, Nakamura K, Matsumoto Y, Nakashima Y, Yamasaki S, Ota A, Hiramine S, Takayama K, Ikezaki H, Toyoda K, Ogawa E, Shimono N.
J Infect Chemother. 2022 Aug;28(8):1208-1211.
7.
Impact of the PNPLA3 genotype on the risk of hepatocellularcarcinoma after hepatitis C virus eradication Ohta A, Ogawa E, Murata M, Matsumoto Y, Yamasaki S, Ikezaki H, Furusyo N.
J Med Virol. 2022 Oct;94(10):5007-5014.
8.
Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study.
Ogawa E, Nakamuta M, Koyanagi T, Ooho A, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Satoh T, Takahashi K, Azuma K, Yamashita N, Yamashita N, Sugimoto R, Amagase H, Kuniyoshi M, Ichiki Y, Morita C, Kato M, Shimoda S, Nomura H, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group.
Aliment Pharmacol Ther. 2022 Aug;56(4):713-722.
9.
Clinical characteristics and factors related to infection with SCCmec type II and IV Methicillin-resistant Staphylococcus aureus in a Japanese secondary care facility: a single-center retrospective study.
Nakano Y, Murata M, Matsumoto Y, Toyoda K, Ota A, Yamasaki S, Otakeno H, Yokoo K, Shimono N.
J Glob Antimicrob Resist. 2022 Dec;31:355-362.
10.
Dynamics of anti-spike IgG antibody after a third BNT162b2 COVID-19 vaccination in Japanese health care workers. Ikezaki H, Nomura H, Shimono N.
Heliyon. 2022 Dec;8(12):e12125.

＜研究分野・研究実績トップへ戻る

ページの先頭へ移動する